Pfizer, Inc. · NYSE:PFE
Pfizer — UBS 2012 Global Healthcare Conference
15 slides from Pfizer's conference presentation, Sep 20, 2012
Slide 1: UBS 2012 Global Healthcare Conference
UBS 2012 Global Healthcare Conference Pfizer Worldwide Research & Development Mikael Dolsten, M.D., Ph.D. September 20, 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements • Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2011 Annual Re
Slide 3: Pfizer R&D Strategy ― 3 Major Priorities
Pfizer R&D Strategy ― 3 Major Priorities Delivering the Innovating New R&D Ecosystem Portfolio Capabilities of the Future Sharpening focus in areas Investing in the Highly networked R&D with greatest scientific & technologies to enable & superior outcomes in commercial ROI tomorrow’s products Precis
Slide 4: Improving R&D Return on Investment
Improving R&D Return on Investment Unlocking Additional Value for Shareholders Three Key Principles 1 2 3 Greater Strategic Differentiated Focus Externalization Innovation Quality Probability Speed Cost of Output of Success • Termination of numerous non-core research projects • Neusentis (Pain) unit
Slide 5: Today's Key Late Stage Assets
Today’s Key Late Stage Assets Key Post-POC Programs Key Products In Registration Eliquis™ (apixaban) Eliquis™ (apixiban) Venous Thromboembolism Treatment Stroke Prevention in AFib; US/EU/Japan Inlyta™ Tofacitinib First Line Renal Cell Carcinoma Rheumatoid Arthritis; US/EU/Japan Tofacitinib Tafamidis
Slide 6: Precision Medicine R&D Shaping a Differentiated Pipeline
Precision Medicine R&D Shaping a Differentiated Pipeline Right Drug Right Target Right Patient (or Combinations) Selective design and Genetic validation; Rare Phenotyping and delivery; combinations phenotypes Genotyping for complex diseases PCSK9 Inotuzumab Nav family (targeted inhibition) PI3K/mTOR
Slide 7: Coupled with Leading Technology Platforms Across Modalities
Coupled with Leading Technology Platforms Across Modalities Pfizer leads in cutting-edge …And is building technology platforms….. technologies of the future Vaccines Inflammation & Tissue-Specific Immunology NCEs CovX Bodies Peptides ADCs Oncology Neuroscience Targeted Antibody Mixtures IgG Heterodi
Slide 8: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Inflammation Beyond RA: Transforming Chronic Disease IL6, MAdCAM P38, IL7R 8
Slide 9: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Inflammation Metabolic Diseases Beyond RA: New Paths to Transforming Chronic Sustained Leadership Disease IL6, MAdCAM PCSK9, Gka P38, IL7R PDE5, FGF21 9
Slide 10: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO 10
Slide 11: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Platfo
Slide 12: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuros
Slide 13: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuros
Slide 14: Next Wave Pipeline Shapes the Future
Next Wave Pipeline Shapes the Future Immunology & Cardiovascular & Oncology Inflammation Metabolic Diseases Beyond RA: New Paths to Power of Precision Transforming Chronic Sustained Leadership Medicine Disease IL6, MAdCAM PCSK9, Gka PI3K/mTOR, 5T4 P38, IL7R PDE5, FGF21 PD-332991, SMO Vaccines Neuros
Slide 15: Thank You
THANK YOU -